Progenics Pharmaceuticals 142 Percent Price Target From Cantor Fitzgerald

Cantor Fitzgerald really went out high on Progenics Pharmaceuticals, or did they? Needham and Company also gave this stock its highest Strong Buy rating too.

Progenics Pharmaceuticals had its price target set to $15 by Cantor Fitzgerald. Cantor Fitzgerald has a Buy rating on the stock. Cantor Fitzgerald has struggled over the last year with its performance; however, Needham and Company hasn't.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Flexion Therapeutics Stock Higher on FDA Approval of Zilretta

Flexion Therapeutics stock has rocketed higher on FDA approval of Zilretta. Zilretta is the first and only extended-release, intra-articular injection for osteoarthritis knee pain.

Michael Clayman, M.D., President and Chief Executive Officer of Flexion said, "The approval of Zilretta marks a major advancement in the treatment landscape for managing OA knee pain. It comes at a time when our society is in urgent need of non-addictive therapies to help the millions of Americans who suffer from this condition. We believe that Zilretta has the potential to be a transformative medicine for the more than five million patients who receive an intra-articular injection for OA knee pain each year."

Zilretta's peak potential sales could hit $750 million but that could be a conservative estimate. With additional revenues from label expansion and potential new indications such as osteoarthritis of the hip and shoulder (for which clinical trials are anticipated to initiate by the end of this year), Zilretta's sales could easily top $1 billion and that doesn't include international sales.

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Jazz Pharmaceuticals Announces Positive Results From Phase 3 TONES 3 and TONES 4

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

Sell Exact Sciences For a 55% Win!

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.

ARIAD Pharmaceuticals Sell For 86.7% Win!

TO READ THE FULL STORY SUBSCRIBE OR SIGN IN

The Computer and Technology portfolio is up more than 440% in the last 6 months! Get these stock picks and more by signing up for the premium service.